218 related articles for article (PubMed ID: 34019108)
1. Effects of strong and moderate CYP3A4 inducers on the pharmacokinetics of fedratinib in healthy adult participants.
Ogasawara K; Kam J; Thomas M; Liu L; Liu M; Xue Y; Surapaneni S; Carayannopoulos LN; Zhou S; Palmisano M; Krishna G
Cancer Chemother Pharmacol; 2021 Sep; 88(3):369-377. PubMed ID: 34019108
[TBL] [Abstract][Full Text] [Related]
2. Effects of repeated oral doses of ketoconazole on a sequential ascending single oral dose of fedratinib in healthy subjects.
Ogasawara K; Xu C; Kanamaluru V; Palmisano M; Krishna G
Cancer Chemother Pharmacol; 2020 May; 85(5):899-906. PubMed ID: 32248324
[TBL] [Abstract][Full Text] [Related]
3. An Open-Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants.
Li J; Rockich K; Yuska B; Zhou G; Epstein N; Punwani N; Chen X; Yeleswaram S
J Clin Pharmacol; 2020 Nov; 60(11):1519-1526. PubMed ID: 32515832
[TBL] [Abstract][Full Text] [Related]
4. Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach.
Ogasawara K; LoRusso PM; Olszanski AJ; Rixe O; Xu C; Yin J; Palmisano M; Krishna G
Cancer Chemother Pharmacol; 2020 Jul; 86(1):87-95. PubMed ID: 32537715
[TBL] [Abstract][Full Text] [Related]
5. Effect of fluconazole on the pharmacokinetics of a single dose of fedratinib in healthy adults.
Chen Y; Ogasawara K; Wood-Horrall R; Thomas M; Thomas M; He B; Liu L; Xue Y; Surapaneni S; Carayannopoulos LN; Zhou S; Palmisano M; Krishna G
Cancer Chemother Pharmacol; 2022 Oct; 90(4):325-334. PubMed ID: 36001108
[TBL] [Abstract][Full Text] [Related]
6. Physiologically based pharmacokinetic modeling to assess metabolic drug-drug interaction risks and inform the drug label for fedratinib.
Wu F; Krishna G; Surapaneni S
Cancer Chemother Pharmacol; 2020 Oct; 86(4):461-473. PubMed ID: 32886148
[TBL] [Abstract][Full Text] [Related]
7. Physiologically Based Pharmacokinetic Modeling for Maribavir to Inform Dosing in Drug-Drug Interaction Scenarios with CYP3A4 Inducers and Inhibitors.
Chen G; Sun K; Michon I; Barter Z; Neuhoff S; Ghosh L; Ilic K; Song IH
J Clin Pharmacol; 2024 May; 64(5):590-600. PubMed ID: 38009271
[TBL] [Abstract][Full Text] [Related]
8. Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers.
Tugnait M; Gupta N; Hanley MJ; Sonnichsen D; Kerstein D; Dorer DJ; Venkatakrishnan K; Narasimhan N
Clin Pharmacol Drug Dev; 2020 Feb; 9(2):214-223. PubMed ID: 31287236
[TBL] [Abstract][Full Text] [Related]
9. The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers.
Shi JG; Chen X; Emm T; Scherle PA; McGee RF; Lo Y; Landman RR; McKeever EG; Punwani NG; Williams WV; Yeleswaram S
J Clin Pharmacol; 2012 Jun; 52(6):809-18. PubMed ID: 21602517
[TBL] [Abstract][Full Text] [Related]
10. Phase 1 study to evaluate the effects of rifampin or itraconazole on the pharmacokinetics of limertinib (ASK120067), a novel mutant-selective inhibitor of the epidermal growth factor receptor in healthy Chinese subjects.
Cao B; Huang L; Liu M; Lin H; Ma T; Zhao Y; Geng Y; Yang Y; Guo H; Li J
Expert Opin Drug Metab Toxicol; 2023 Sep; 19(9):653-664. PubMed ID: 37811634
[TBL] [Abstract][Full Text] [Related]
11. The effect of rifampin on the pharmacokinetics of famitinib in healthy subjects.
Li T; Li X; Jiang X; Wang C; Sun F; Liu Y; Lin P; Shi P; Fu Y; Gao X; Zhang Y; Cao Y
Cancer Chemother Pharmacol; 2022 Nov; 90(5):409-415. PubMed ID: 36107220
[TBL] [Abstract][Full Text] [Related]
12. Effects of Itraconazole and Rifampin on the Pharmacokinetics of Mobocertinib (TAK-788), an Oral Epidermal Growth Factor Receptor Inhibitor, in Healthy Volunteers.
Zhang S; Jin S; Griffin C; Feng Z; Lin J; Venkatakrishnan K; Gupta N
Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1044-1053. PubMed ID: 34145979
[TBL] [Abstract][Full Text] [Related]
13. Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling.
de Zwart L; Snoeys J; De Jong J; Sukbuntherng J; Mannaert E; Monshouwer M
Clin Pharmacol Ther; 2016 Nov; 100(5):548-557. PubMed ID: 27367453
[TBL] [Abstract][Full Text] [Related]
14. Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults.
Shumaker RC; Aluri J; Fan J; Martinez G; Thompson GA; Ren M
Clin Drug Investig; 2014 Sep; 34(9):651-9. PubMed ID: 25022720
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of the effect of repeated oral doses of pantoprazole on the pharmacokinetics of a single dose of fedratinib in healthy male subjects.
Ogasawara K; Vince B; Xu C; Zhang M; Palmisano M; Krishna G
Cancer Chemother Pharmacol; 2020 May; 85(5):995-1001. PubMed ID: 32318809
[TBL] [Abstract][Full Text] [Related]
16. The Drug-Drug Interaction Profile of Presatovir.
Xin Y; Weng W; Murray BP; Eisenberg EJ; Chien JW; Ling J; Silverman JA
J Clin Pharmacol; 2018 Jun; 58(6):771-780. PubMed ID: 29412463
[TBL] [Abstract][Full Text] [Related]
17. Effect of a moderate CYP3A inducer efavirenz on the pharmacokinetics of fuzuloparib: An open-label, fixed sequence study in Chinese healthy male subjects.
Hu L; Dou T; Sun Q; Tang L; Cai M; Qian W; Wang H
Invest New Drugs; 2023 Apr; 41(2):276-283. PubMed ID: 36800130
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and tolerability of fedratinib, an oral, selective Janus kinase 2 inhibitor, in subjects with renal or hepatic impairment.
Ogasawara K; Smith WB; Xu C; Yin J; Palmisano M; Krishna G
Cancer Chemother Pharmacol; 2020 Jun; 85(6):1109-1117. PubMed ID: 32449142
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects.
Zahir H; Greenberg J; Shuster D; Hsu C; Watanabe K; LaCreta F
Clin Pharmacokinet; 2022 Nov; 61(11):1623-1639. PubMed ID: 36264536
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the effect of multiple doses of rifampin on the pharmacokinetics and safety of ponatinib in healthy subjects.
Narasimhan NI; Dorer DJ; Davis J; Turner CD; Sonnichsen D
Clin Pharmacol Drug Dev; 2015 Sep; 4(5):354-60. PubMed ID: 27137144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
